You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on PD-L1 biomarkers.
Merck announced that the FDA accepted supplemental biologic license applications for the checkpoint inhibitor for early- and later-stage triple-negative breast cancer.
In a Phase Ia/Ib study, the anti-TIGIT antibody and Tecentriq combination had better anti-tumor activity than tiragolumab alone, particularly in PD-L1 expressing lung cancers.
The studies highlighted the activity of three drugs in NSCLC patients characterized by HER2 mutations, CECAM5 overexpression, and high PD-L1 expression.
In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.
Bristol Myers Squibb is hoping that the durable responses seen with the combined immunotherapy drugs will convince doctors to prescribe it for their patients.
The latest approval is immunotherapy Tecentriq's fourth indication in non-small cell lung cancer and fifth indication in lung cancer.
This approval, based on the part 1a results from the Phase III CheckMate-227 trial, is the fifth indication for this drug combination.
In KEYNOTE-355, patients with PD-L1 expression greater than or equal to a combined positive score of 10 had improved progression-free survival on first-line Keytruda and chemo.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The data from the trial will support regulatory submissions in the US and EU for Libtayo as a first-line option for PD-L1 positive non-small cell lung cancer patients.